Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Setting up a zero based budget can transform your financial management. Discover the essential steps to take control of your spending.
21,901 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
A high-profile insider sale at PTC Therapeutics coincides with a milestone for product revenue. This article breaks d...
June inflation cooled, sparking a rally in crypto markets. Ethereum led the way with a double‑digit gain, while Bitco...
Stellantis has faced a painful setback, but a bold turnaround plan could spark renewed interest. This guide breaks do...
A New Jersey homeowner filed a lawsuit against Newrez LLC (Shellpoint Mortgage Servicing), accusing years of improper...
Explore a fresh, practical comparison of FSTA and XLP. Learn how these popular consumer staples ETFs differ in index ...
A surge in AI workloads is testing chipmakers worldwide. This piece explains why tsmc can't make chips fast enough, w...
A notable fund adds Masimo stock, signaling confidence in noninvasive monitoring tech. This analysis breaks down the ...
When two people share a life, their retirement plan should share the payoff. This guide breaks down why couples often...
Today’s gain in Viking Therapeutics stock more has traders buzzing, but the move isn’t tied to a single headline. Thi...
A surge in exports, a stronger currency, and deep reform push lift a frontier market into fresh highs. The world’s ho...
A 58-year-old with $800,000 saved is considering retirement in five years without Social Security, weighing a bridge ...